ResMic®

• ResMic^® resorbs quickly to insure a recanalization of the arteries within one week. A rapid recanalization is required to preserve organs (e.g: uterus after fibroids embolization), or in case of repeated embolization (e.g: tumor recurrence).
• ResMic^® is loadable with various drugs (anticancer, antiangiogenic agents, others drugs) to provide a local drug delivery. ResMic^® releases 100% of its drug content.

ResMic^® is intended for:

•  Embolization of benign tumors such as Uterine Fibroids. In a first phase, ResMic^® insures an ischemia of uterine fibroids, leading to their necrosis. In a second phase, ResMic^® completely resorbs, allowing the recanalization of uterine arteries.
• Embolization of bleedings (hemostasis). At an early stage, ResMic^® stops the flow of the bleeding vessels during the time needed for hemostasis and tissue repair. Soon after, the resorption of ResMic^® allows blood to flow again to feed the organ (kidney, uterus, spleen, lung, liver…).
• Chemo-embolization of malignant hypervascular tumors of liver (HCC, CRC liver metastasis) or other organs. ResMic^® is loaded with an anticancer agent just before the treatment. ResMic^® acts in three steps: (1) it blocks the tumor feeding arterioles and provokes an ischemia-induced necrosis, (2) the anticancer drug releases from ResMic^® to complete tumor necrosis and prevent tumor regrowth, (3) ResMic^® resorbs and the arterioles recanalize, thus allowing to repeat chemoembolization.

ResMic^® is easy to use

• Spherical and Calibrated in 200 µm size ranges between 50 µm and 1200 µm to target the occlusion level from proximal to distal vessels.
•  Preparation is  quick and easy: ResMic^® is supplied dry, lyophilized and it is hydrated in minutes in injectable solutions (physiological saline, water…). It is hydrophilic and easily mixed in contrast media.
• Easy to inject in  microcatheters without risk of blockade since it is elastic and tolerates a good compression in small catheter lumens.

 ResMic^® resorbs completely in a controlled time and is well-tolerated

• Spontaneous hydrolysis of ResMic^® occurs in body fluids, and resorption is completed in two or three days. Degradation byproducts are fully eliminated by renal filtration.
• Implantation in tissues triggers basically no inflammatory reaction. After resorption, neither scar nor chronic inflammation response remains.

 ResMic^® is rapidly loadable for Chemoembolization with:

• cytostatic drugs (Doxorubicin, Irinotecan). ResMic^® loading capacity is similar to non resorbable drug eluting microspheres.
• anti-angiogenic agents (Bevacizumab and Sunitinib), anti inlammatory drugs, pain-killers.
• other molecules of interest such as bFGF,  polyplexes of nucleic acids (SiRNA, genes for gene therapy).

ResMic^® performances and tolerance have been extensively evaluated in preclinical studies.